Novel pharmacotherapeutic approaches in treatment of alcohol addiction

Rashidi Mohamed Pakri Mohamed, Jaya Kumar, Shihad Udin Ahmad, Isa Naina Mohamed

Research output: Contribution to journalReview article

Abstract

In the past two decades, the search for novel pharmacotherapies to treat alcohol addiction has been a global endeavor. This has resulted in several drugs that have been approved and successfully marketed for public use while some are still in the testing phase. These pharmacological agents, though effective for the treatment of alcoholism, are not without shortcomings; such as abuse potential, serious mental and physical adverse effects, interaction with alcohol and also poor metabolism and excretion. As more is being understood about the neurobiology of alcohol addiction as well as the unique pharmacological action of these drugs, new agents are evaluated for potential benefits when used as an adjunct in combination therapy. This review article summarizes the novel pharmacotherapeutic approaches used in the treatment of alcohol addiction by focusing on the drugs, which include neramexane, gabapentin, baclofen, aripiprazole, nalmafene, and quetiapine.

Original languageEnglish
Pages (from-to)1378-1390
Number of pages13
JournalCurrent Drug Targets
Volume19
Issue number12
DOIs
Publication statusPublished - 1 Jan 2018

Fingerprint

Alcoholism
Alcohols
Pharmaceutical Preparations
Pharmacology
Drug therapy
Baclofen
Neurobiology
Therapeutics
Metabolism
Drug Therapy
Testing

Keywords

  • Alcohol
  • Aripiprazole
  • Baclofen
  • Gabapentin
  • Nalmafene
  • Neramexane
  • Quetiapine

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology
  • Drug Discovery
  • Clinical Biochemistry

Cite this

Novel pharmacotherapeutic approaches in treatment of alcohol addiction. / Pakri Mohamed, Rashidi Mohamed; Kumar, Jaya; Ahmad, Shihad Udin; Naina Mohamed, Isa.

In: Current Drug Targets, Vol. 19, No. 12, 01.01.2018, p. 1378-1390.

Research output: Contribution to journalReview article

@article{abd77fa1143f4591b14bb532eef12f1a,
title = "Novel pharmacotherapeutic approaches in treatment of alcohol addiction",
abstract = "In the past two decades, the search for novel pharmacotherapies to treat alcohol addiction has been a global endeavor. This has resulted in several drugs that have been approved and successfully marketed for public use while some are still in the testing phase. These pharmacological agents, though effective for the treatment of alcoholism, are not without shortcomings; such as abuse potential, serious mental and physical adverse effects, interaction with alcohol and also poor metabolism and excretion. As more is being understood about the neurobiology of alcohol addiction as well as the unique pharmacological action of these drugs, new agents are evaluated for potential benefits when used as an adjunct in combination therapy. This review article summarizes the novel pharmacotherapeutic approaches used in the treatment of alcohol addiction by focusing on the drugs, which include neramexane, gabapentin, baclofen, aripiprazole, nalmafene, and quetiapine.",
keywords = "Alcohol, Aripiprazole, Baclofen, Gabapentin, Nalmafene, Neramexane, Quetiapine",
author = "{Pakri Mohamed}, {Rashidi Mohamed} and Jaya Kumar and Ahmad, {Shihad Udin} and {Naina Mohamed}, Isa",
year = "2018",
month = "1",
day = "1",
doi = "10.2174/1389450119666180523092534",
language = "English",
volume = "19",
pages = "1378--1390",
journal = "Current Drug Targets",
issn = "1389-4501",
publisher = "Bentham Science Publishers B.V.",
number = "12",

}

TY - JOUR

T1 - Novel pharmacotherapeutic approaches in treatment of alcohol addiction

AU - Pakri Mohamed, Rashidi Mohamed

AU - Kumar, Jaya

AU - Ahmad, Shihad Udin

AU - Naina Mohamed, Isa

PY - 2018/1/1

Y1 - 2018/1/1

N2 - In the past two decades, the search for novel pharmacotherapies to treat alcohol addiction has been a global endeavor. This has resulted in several drugs that have been approved and successfully marketed for public use while some are still in the testing phase. These pharmacological agents, though effective for the treatment of alcoholism, are not without shortcomings; such as abuse potential, serious mental and physical adverse effects, interaction with alcohol and also poor metabolism and excretion. As more is being understood about the neurobiology of alcohol addiction as well as the unique pharmacological action of these drugs, new agents are evaluated for potential benefits when used as an adjunct in combination therapy. This review article summarizes the novel pharmacotherapeutic approaches used in the treatment of alcohol addiction by focusing on the drugs, which include neramexane, gabapentin, baclofen, aripiprazole, nalmafene, and quetiapine.

AB - In the past two decades, the search for novel pharmacotherapies to treat alcohol addiction has been a global endeavor. This has resulted in several drugs that have been approved and successfully marketed for public use while some are still in the testing phase. These pharmacological agents, though effective for the treatment of alcoholism, are not without shortcomings; such as abuse potential, serious mental and physical adverse effects, interaction with alcohol and also poor metabolism and excretion. As more is being understood about the neurobiology of alcohol addiction as well as the unique pharmacological action of these drugs, new agents are evaluated for potential benefits when used as an adjunct in combination therapy. This review article summarizes the novel pharmacotherapeutic approaches used in the treatment of alcohol addiction by focusing on the drugs, which include neramexane, gabapentin, baclofen, aripiprazole, nalmafene, and quetiapine.

KW - Alcohol

KW - Aripiprazole

KW - Baclofen

KW - Gabapentin

KW - Nalmafene

KW - Neramexane

KW - Quetiapine

UR - http://www.scopus.com/inward/record.url?scp=85052205421&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85052205421&partnerID=8YFLogxK

U2 - 10.2174/1389450119666180523092534

DO - 10.2174/1389450119666180523092534

M3 - Review article

VL - 19

SP - 1378

EP - 1390

JO - Current Drug Targets

JF - Current Drug Targets

SN - 1389-4501

IS - 12

ER -